Cargando…
Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent
Targeted therapies are a promising alternative to conventional chemotherapy, with an increasing number of therapeutics targeting specific molecular aberrancies in cancer cells. One of the emerging targets for directed cancer treatments is fibroblast growth factor receptors (FGFRs), which are known t...
Autores principales: | Jendryczko, Karolina, Rzeszotko, Jakub, Krzyscik, Mateusz Adam, Szymczyk, Jakub, Otlewski, Jacek, Szlachcic, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636100/ https://www.ncbi.nlm.nih.gov/pubmed/34867353 http://dx.doi.org/10.3389/fphar.2021.748936 |
Ejemplares similares
-
Drug Conjugation via Maleimide–Thiol Chemistry
Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1
Peptibodies
por: Jendryczko, Karolina, et al.
Publicado: (2022) -
FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1
por: Jendryczko, Karolina, et al.
Publicado: (2020) -
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
por: Szymczyk, Jakub, et al.
Publicado: (2021) -
Identification of a peptide antagonist of the FGF1–FGFR1 signaling axis by phage display selection
por: Lipok, Magdalena, et al.
Publicado: (2019) -
Site-Specific, Stoichiometric-Controlled, PEGylated
Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin
Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast
Growth Factor Receptor 1 (FGFR1)
por: Krzyscik, Mateusz Adam, et al.
Publicado: (2020)